Ching Hsu

485 total citations
23 papers, 356 citations indexed

About

Ching Hsu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ching Hsu has authored 23 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ching Hsu's work include Colorectal Cancer Treatments and Studies (4 papers), Venous Thromboembolism Diagnosis and Management (4 papers) and Pain Mechanisms and Treatments (3 papers). Ching Hsu is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Venous Thromboembolism Diagnosis and Management (4 papers) and Pain Mechanisms and Treatments (3 papers). Ching Hsu collaborates with scholars based in United States, Japan and Germany. Ching Hsu's co-authors include Domenico Merante, Julio Rosenstock, Uma Sharma, Hamim Zahir, Byron Cryer, Roger G. Berlin, Stephen A. Cooper, Suman Wason, Oleg Gladkov and Vladimir Vladimirov and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Diabetes Care.

In The Last Decade

Ching Hsu

23 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ching Hsu United States	10	130	107	84	79	64	23	356
Iván Cabezas‐Rodríguez Spain	11	60 0.5×	33 0.3×	55 0.7×	62 0.8×	12 0.2×	23	532
Francesco Trimarchi Italy	16	46 0.4×	93 0.9×	32 0.4×	136 1.7×	22 0.3×	27	789
Valentina Angelini Italy	9	65 0.5×	35 0.3×	22 0.3×	91 1.2×	14 0.2×	14	509
Zhuo Liu China	12	21 0.2×	71 0.7×	42 0.5×	113 1.4×	15 0.2×	43	401
Nina Sarah Gowert Germany	9	126 1.0×	28 0.3×	24 0.3×	71 0.9×	12 0.2×	9	375
W. I. Bry United States	7	147 1.1×	31 0.3×	29 0.3×	152 1.9×	16 0.3×	15	447
Malca Kierson United States	4	227 1.7×	143 1.3×	18 0.2×	205 2.6×	18 0.3×	6	462
Hong Qiu United States	12	19 0.1×	65 0.6×	15 0.2×	138 1.7×	26 0.4×	31	342
Pascale Plas France	14	163 1.3×	63 0.6×	23 0.3×	207 2.6×	20 0.3×	24	623

Countries citing papers authored by Ching Hsu

Since Specialization

Citations

This map shows the geographic impact of Ching Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching Hsu more than expected).

Fields of papers citing papers by Ching Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching Hsu. The network helps show where Ching Hsu may publish in the future.

Co-authorship network of co-authors of Ching Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Ching Hsu. A scholar is included among the top collaborators of Ching Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching Hsu. Ching Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, James Chih‐Hsin, Wu‐Chou Su, Chao‐Hua Chiu, et al.. (2023). Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. Investigational New Drugs. 41(2). 306–316. 8 indexed citations

Zahir, Hamim, Ophelia Yin, Ching Hsu, et al.. (2023). Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy. Clinical Pharmacology in Drug Development. 12(5). 475–483. 4 indexed citations

Prat, Aleix, Shanu Modi, Junji Tsurutani, et al.. (2023). Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04. Cancer Research. 83(5_Supplement). HER2–18. 5 indexed citations

Zahir, Hamim, Jonathan Greenberg, Dale E. Shuster, et al.. (2022). Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. Clinical Pharmacokinetics. 61(11). 1623–1639. 5 indexed citations

Zahir, Hamim, Jonathan Greenberg, Ching Hsu, et al.. (2022). Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics. The Journal of Clinical Pharmacology. 62(8). 992–1005. 3 indexed citations

Mims, Alice S., Melhem Solh, Jennifer N. Saultz, et al.. (2021). Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood. 138(Supplement 1). 3420–3420. 2 indexed citations

Mims, Alice S., Melhem Solh, Uma Borate, et al.. (2020). Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood. 136(Supplement 1). 14–15. 2 indexed citations

Arnold, Lesley M., Susan D. Whitaker, Ching Hsu, David R. Jacobs, & Domenico Merante. (2019). Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Current Medical Research and Opinion. 35(10). 1825–1835. 26 indexed citations

Pemmaraju, Naveen, Uma Borate, Melhem Solh, et al.. (2019). Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 1391–1391. 4 indexed citations

10.

Hsu, Ching, Sarayu Ramachandran, Adam Jacobi, et al.. (2018). Reproducibility of thrombus volume quantification in multicenter computed tomography pulmonary angiography studies. World Journal of Radiology. 10(10). 124–134. 3 indexed citations

11.

Hsu, Ching, et al.. (2018). Effect of varying computed tomography acquisition and reconstruction parameters on semi-automated clot volume quantification. World Journal of Radiology. 10(3). 24–29. 2 indexed citations

12.

Brown, Karen, Jeanne Mendell, Shoichi Ohwada, et al.. (2018). Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. Pharmacology Research & Perspectives. 6(5). e00418–e00418. 23 indexed citations

13.

Lasch, Kathryn, et al.. (2018). An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Management. 2018. 1–8. 9 indexed citations

14.

Tachibana, Masaya, Naotoshi Yamamura, George Atiee, et al.. (2018). Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study. British Journal of Clinical Pharmacology. 84(10). 2317–2324. 14 indexed citations

15.

Merante, Domenico, et al.. (2017). Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study. Pain Medicine. 18(11). 2198–2207. 29 indexed citations

16.

Eng, Cathy, Alberto Bessudo, Lowell L. Hart, et al.. (2016). A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy. International Journal of Cancer. 139(1). 177–186. 52 indexed citations

17.

Rosenstock, Julio, et al.. (2014). Efficacy and Safety of Mirogabalin (DS-5565) for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo- and Active Comparator–Controlled, Adaptive Proof-of-Concept Phase 2 Study. Diabetes Care. 37(12). 3253–3261. 79 indexed citations

18.

Eng, Cathy, Lowell L. Hart, Oleg Gladkov, et al.. (2013). A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.. Journal of Clinical Oncology. 31(15_suppl). 3508–3508. 22 indexed citations

19.

Moberly, James B., Shashank Rohatagi, Hamim Zahir, et al.. (2011). Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1‐Phosphate Receptor‐1 Modulator. The Journal of Clinical Pharmacology. 52(7). 996–1006. 14 indexed citations

20.

Cryer, Byron, Roger G. Berlin, Stephen A. Cooper, Ching Hsu, & Suman Wason. (2005). Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-tereated healthy adult volunteers. Clinical Therapeutics. 27(2). 185–191. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact